BigBear.ai appoints Sean Ricker as chief financial officer
UroGen Pharma Ltd. (NASDAQ:URGN) announced Wednesday that shareholders approved all proposals at the company’s 2025 Annual Meeting held Tuesday.
Shareholders elected seven directors to serve until the next annual meeting. The elected directors are Arie Belldegrun, M.D.; Elizabeth Barrett; Cynthia M. Butitta; Stuart Holden, M.D.; James A. Robinson, Jr.; Leana S. Wen, M.D., M.Sc.; and Daniel G. Wildman. Vote totals for each nominee ranged from 19,767,638 to 21,700,880 in favor. The company maintains strong financial health with a current ratio of 4.14, indicating solid liquidity to meet short-term obligations.
The meeting also saw approval of UroGen’s Amended and Restated Non-Employee Director and Officer Compensation Policy, with 17,894,986 votes for and 3,295,431 against.
Shareholders approved amendments to the 2017 Equity Incentive Plan, increasing the number of ordinary shares authorized for issuance under the plan by 2,750,000 shares. This proposal received 18,403,175 votes for and 2,777,281 against.
On an advisory basis, shareholders approved the compensation paid to the company’s named executive officers, with 18,852,928 votes in favor and 2,217,830 against. Shareholders also voted to hold future advisory votes on executive compensation annually, with 21,144,259 votes for a one-year frequency.
Additionally, shareholders approved the engagement of PricewaterhouseCoopers LLP as UroGen’s independent auditor until the 2026 annual meeting, with 32,922,800 votes for and 136,141 against.
The board determined that future advisory votes on executive compensation will be held every year until the next required non-binding advisory vote on frequency, which will occur no later than the 2031 annual meeting. While the company boasts an impressive gross profit margin of 88.54%, InvestingPro subscribers can access additional insights, including detailed financial health scores and a comprehensive analysis of UroGen’s market position among over 1,400 US stocks covered in Pro Research Reports.
All information in this article is based on a statement from UroGen Pharma Ltd.’s filing with the Securities and Exchange Commission.
In other recent news, UroGen Pharma reported its second-quarter 2025 financial results, showing net product revenues of $24.2 million, which exceeded the forecasted $23.13 million and marked an 11% year-over-year growth. Despite this revenue increase, the company recorded a net loss of $1.50 per share, larger than the anticipated loss of $0.83 per share. H.C. Wainwright subsequently lowered its price target for UroGen Pharma from $50.00 to $40.00, maintaining a Buy rating. Guggenheim, on the other hand, raised its price target to $32.00, emphasizing the potential of the Zusduri launch in the U.S. market. Piper Sandler initiated coverage with an Overweight rating, citing investor confidence in the Zusduri launch. TD Cowen reiterated a Buy rating and a $35.00 price target, noting the promising early progress of Zusduri’s launch. These developments highlight the varying analyst perspectives on UroGen Pharma’s financial performance and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.